amphotericin B
... • The choice of antifungal agents could be a combination of Amphotericin B and Flucytosine(5-FC) for systemic fungal infection, such as cryptococcal meningitis. But this therapy is useful only when the patient had a normal renal function with hemodialysis, since both drugs have very strong nephroto ...
... • The choice of antifungal agents could be a combination of Amphotericin B and Flucytosine(5-FC) for systemic fungal infection, such as cryptococcal meningitis. But this therapy is useful only when the patient had a normal renal function with hemodialysis, since both drugs have very strong nephroto ...
T Thalidomide
... Oral bioavailability of thalidomide is not known due to poor aqueous solubility. Slowly absorbed from the GI tract with peak plasma levels reached 3–6 hours after oral administration. ...
... Oral bioavailability of thalidomide is not known due to poor aqueous solubility. Slowly absorbed from the GI tract with peak plasma levels reached 3–6 hours after oral administration. ...
Durogesic Article-30 referral
... The proposed wording has been developed to align the populations evaluated in clinical studies and to maintain alignment between the indications for both adult and paediatric patients. Section 4.2 – Posology and method of administration For safety reasons, addition of the text that the lowest effect ...
... The proposed wording has been developed to align the populations evaluated in clinical studies and to maintain alignment between the indications for both adult and paediatric patients. Section 4.2 – Posology and method of administration For safety reasons, addition of the text that the lowest effect ...
atryn
... dose was shown to be safe in a second rat study when administered around parturition and during lactation where the no adverse effect level for dam and pups was 210 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always pred ...
... dose was shown to be safe in a second rat study when administered around parturition and during lactation where the no adverse effect level for dam and pups was 210 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always pred ...
Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY
... *three of these patients discontinued treatment after receiving sorafenib 400 mg bid **three of these patients received 200 mg bid due to a dosing error ***n=9 for sorafenib and n=1 for gefitinib ...
... *three of these patients discontinued treatment after receiving sorafenib 400 mg bid **three of these patients received 200 mg bid due to a dosing error ***n=9 for sorafenib and n=1 for gefitinib ...
Cocaine & Amphetamines
... Effects onset in seconds, peaks in 5 minutes and lasts about 30 minutes ...
... Effects onset in seconds, peaks in 5 minutes and lasts about 30 minutes ...
Therapeutic Parenteral Drug Administration and In
... pain. In this study, patients developing moderate -to-severe pain after third molar extraction under local anesthesia were randomized to one of the 4 SC injections: 25, 50, or 75 mg diclofenac, or placebo. The pain intensity differences were measured at 1.5 hours post dose and showed was higher in ...
... pain. In this study, patients developing moderate -to-severe pain after third molar extraction under local anesthesia were randomized to one of the 4 SC injections: 25, 50, or 75 mg diclofenac, or placebo. The pain intensity differences were measured at 1.5 hours post dose and showed was higher in ...
Motofen® Tablets
... distinguish from symptoms associated with the diarrheal syndrome. However, the following events were reported at the stated frequencies: Gastrointestinal: Nausea, 1 in 15 patients; vomiting, 1 in 30 patients; dry mouth, 1 in 30 patients; epigastric distress, 1 in 100 patients; and constipation, 1 in ...
... distinguish from symptoms associated with the diarrheal syndrome. However, the following events were reported at the stated frequencies: Gastrointestinal: Nausea, 1 in 15 patients; vomiting, 1 in 30 patients; dry mouth, 1 in 30 patients; epigastric distress, 1 in 100 patients; and constipation, 1 in ...
Article in text format ()
... minimum effective dose in phase 2 of the clinical trials than with the methods deployed hitherto. It sounds simple, but this kind of mathematics has not, as yet, arrived in practical applications – even though Holger Dette has been developing the new method since 2008. There are two reasons for the ...
... minimum effective dose in phase 2 of the clinical trials than with the methods deployed hitherto. It sounds simple, but this kind of mathematics has not, as yet, arrived in practical applications – even though Holger Dette has been developing the new method since 2008. There are two reasons for the ...
Antimicrobial Fundamental Concepts
... antibiotic that completely inhibits growth of the specific organism being tested. Minimum bactericidal concentration (MBC) – The MBC is defined as the lowest concentration of antibiotic at which bacteria are killed. Most of the available evidence supports the preferential use of a bactericidal agent ...
... antibiotic that completely inhibits growth of the specific organism being tested. Minimum bactericidal concentration (MBC) – The MBC is defined as the lowest concentration of antibiotic at which bacteria are killed. Most of the available evidence supports the preferential use of a bactericidal agent ...
GENITAL HERPES, GONOCOCCAL, AND CHLAMYDIAL
... genital HSV-2 infections. The 2015 CDC guidelines recommend a dosage of 400 mg PO TID for 7–10 days or 200 mg five times per day for 7–10 days.1 Oral acyclovir has demonstrated efficacy in reducing viral shedding, duration of symptoms, and time to healing of first-episode genital herpes infections. ...
... genital HSV-2 infections. The 2015 CDC guidelines recommend a dosage of 400 mg PO TID for 7–10 days or 200 mg five times per day for 7–10 days.1 Oral acyclovir has demonstrated efficacy in reducing viral shedding, duration of symptoms, and time to healing of first-episode genital herpes infections. ...
Seeking Insight - sun pharma advanced research company
... mean diameter of ~80-120 nm taken on a Malvern’s Zetasizer. ...
... mean diameter of ~80-120 nm taken on a Malvern’s Zetasizer. ...
Lack of Dose Flexibility in Solid Oral Controlled
... pharmacokinetics of whole and half tablets of CR theophylline tablets indicate that half tablets dissolve faster and result in higher plasma levels. Thus, for CR medications, if titration or a change of dose is recommended in the product’s dosing instructions, dose adjustment can be somewhat more on ...
... pharmacokinetics of whole and half tablets of CR theophylline tablets indicate that half tablets dissolve faster and result in higher plasma levels. Thus, for CR medications, if titration or a change of dose is recommended in the product’s dosing instructions, dose adjustment can be somewhat more on ...
SPARC Investor Presentation
... • Phase II study in India ongoing • To be filed in US as 505(b)(2) in Q1 2011-12 An Antihypertensive drug with high dose, high solubility • Phase II study ongoing • To be filed in US as 505(b)(2) in Q2 2011-12 A Cardiovascular agent with high dose and high solubility • Pharmacokinetics studies are o ...
... • Phase II study in India ongoing • To be filed in US as 505(b)(2) in Q1 2011-12 An Antihypertensive drug with high dose, high solubility • Phase II study ongoing • To be filed in US as 505(b)(2) in Q2 2011-12 A Cardiovascular agent with high dose and high solubility • Pharmacokinetics studies are o ...
ASTHMA
... • Fluticasone twice as potent needs half the dose • Thrush and dysphonia decreased by rinsing mouth out after use abd using a spacer ...
... • Fluticasone twice as potent needs half the dose • Thrush and dysphonia decreased by rinsing mouth out after use abd using a spacer ...
Click here for the PowerPoint presentation
... • Sufficiently broad to meet the usual clinical problems • Avoids duplication of clinical effect ...
... • Sufficiently broad to meet the usual clinical problems • Avoids duplication of clinical effect ...
Case-Control Study
... Physostigmine in a dose of 1-2 mg was shown to temporarily reverse CNS depression and reduce seizure-like behaviors in the management of comatose animals (collies) Avermectins do not regulate cholinergic nerve transmissions and both neostigmine and physostigmine are unlikely to be effective Flumazen ...
... Physostigmine in a dose of 1-2 mg was shown to temporarily reverse CNS depression and reduce seizure-like behaviors in the management of comatose animals (collies) Avermectins do not regulate cholinergic nerve transmissions and both neostigmine and physostigmine are unlikely to be effective Flumazen ...
Secondary Stroke Prevention: Implications of the MATCH Trial
... patients with known heart disease, hx of syncope, FH of sudden death or congenital prolonged QT. If ziprasidone is used for any of these patients, a baseline ECG should be obtained before beginning treatment. A subsequent ECG is indicated for symptoms suggestive of a prolonged QT interval (e.g. ...
... patients with known heart disease, hx of syncope, FH of sudden death or congenital prolonged QT. If ziprasidone is used for any of these patients, a baseline ECG should be obtained before beginning treatment. A subsequent ECG is indicated for symptoms suggestive of a prolonged QT interval (e.g. ...
Script Notes - AmeriHealth Caritas Pennsylvania
... N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. ...
... N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. ...
SPARC Investor Presentation - sun pharma advanced research
... • Phase II study in India ongoing • To be filed in US as 505(b)(2) in Q1 2011-12 An Antihypertensive drug with high dose, high solubility • Phase II study ongoing • To be filed in US as 505(b)(2) in Q2 2011-12 A Cardiovascular agent with high dose and high solubility • Pharmacokinetics studies are o ...
... • Phase II study in India ongoing • To be filed in US as 505(b)(2) in Q1 2011-12 An Antihypertensive drug with high dose, high solubility • Phase II study ongoing • To be filed in US as 505(b)(2) in Q2 2011-12 A Cardiovascular agent with high dose and high solubility • Pharmacokinetics studies are o ...
Industrial and household toxicology
... Organic nitrates such as nitroglycerin also are used in explosives…. ...
... Organic nitrates such as nitroglycerin also are used in explosives…. ...
Sympathomimetcs & Parasympatholytics
... Side effects: Like Metaproterenol; tremors and agitation may be prominent Severe agitation seen when administered to ...
... Side effects: Like Metaproterenol; tremors and agitation may be prominent Severe agitation seen when administered to ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.